Mixed Features & Anxious Distress: Recognizing Specifiers in Primary Care

Summary

This peer-to-peer podcast helps primary care providers recognize symptom patterns that may complicate the evaluation of patients presenting with depression or other mood symptoms. Expert faculty discuss mixed features and anxious distress in practical terms, highlighting how these presentations may appear in everyday primary care encounters. The discussion reinforces how broader symptom recognition can support more informed assessment, referral, and individualized management. 

Transcript

Samantha Fox: Welcome to this podcast episode on PrimaryCarePsychiatry.com. My name is Samantha Fox, and I’m a family nurse practitioner, practicing outpatient psychiatry for the past seven years. 

Jamie Fernandez: And I’m Jamie Winderbaum Fernandez, psychiatrist and researcher for almost 20 years, treating mood disorder patients in inpatient and outpatient settings. Currently, I'm the principal investigator and the owner of IPTB Clinical Research in Tampa Bay. 

Samantha Fox: Let’s begin with what we may commonly observe in our clinical practice. So, it’s believed that the primary care setting may be the first real opportunity to identify clinical features of mood disorders, such as major depressive disorder, or MDD, and bipolar disorder. The reason for this is that patients frequently present with depression or other mood symptoms to their general practitioner for initial care.

The Diagnostic and Statistical Manual of Mental Disorders, 5th edition, or DSM-5, provides the standard diagnostic criteria used across psychiatric disorders, establishing a shared clinical language for diagnosis. Within the broader DSM-5 framework, targeted specifiers have been added to further characterize certain psychiatric diagnoses and capture a more specific clinical picture. To be clear, these specifiers are not distinct diagnoses; rather, they are modifiers—used throughout the DSM-5 across a range of psychiatric conditions. This flags a particular symptom pattern and can have implications for how clinicians approach disease management. 

Jamie Fernandez: That’s correct. Specifiers don't change the underlying diagnosis. Instead, they provide additional clinical detail, which can shape how a clinician thinks about a patient's course of treatment going forward.

DSM-5 Diagnostic Criteria and Recognition: Mixed Features

Samantha Fox: Let’s first discuss the mixed features specifier. During a major depressive episode, for example, the mixed features specifier is defined by the presence of at least three of the following manic or hypomanic symptoms during most days of the major depressive episode: 

• Elevated or expansive mood 
• Inflated self-esteem or grandiosity 
• More talkative than usual, pressured speech 
• Flight of ideas or racing thoughts 
• Increased energy or goal-directed activity 
• Increased or excessive involvement in activities with high potential for painful consequences 
• And decreased need for sleep 

Conversely, during a manic or hypomanic episode, mixed features are defined by the presence of at least three depressive symptoms during most days. Depressive symptoms may include sad or depressed mood, diminished interest or pleasure, psychomotor slowing, fatigue or loss of energy, feelings of worthlessness or inappropriate guilt, and thoughts of death.

Jamie Fernandez: The DSM-5 describes it as such: a patient with mixed features may feel depressed and activated at the same time, such as profound sadness alongside manic or hypomanic symptoms, like agitation, racing thoughts, or increased energy. On the other hand, a patient may appear euphoric or irritable on the surface while also privately experiencing depressive symptoms such as guilt, hopelessness, or thoughts of death. 

Samantha Fox: Do we have information on how often mixed features are observed in real-world practice? 

Jamie Fernandez: Good question. We do. In the United States, mixed features have an estimated lifetime prevalence of 15%. A 2026 systematic review offers additional context for the prevalence of this specifier. In various studies, mixed features were observed in approximately 3% to 10% of US patients with major depressive disorder and 9% to 35% of US patients with bipolar disorder. In fact, one US study reported mixed features in more than half of manic or hypomanic episodes.

Samantha Fox: Does meeting criteria for mixed features correlate with disease severity? 

Jamie Fernandez: It does—and this speaks to the overall burden on patients. Patients who meet the mixed features criteria during a depressive episode, regardless of diagnosis, tend to show greater depressive severity and more complex illness overall compared to those without mixed features. These individuals tend to have higher rates of alcohol or substance use, as well as a higher likelihood of comorbidities, such as heart disease. This illustrates the importance of recognizing mixed features and their impact on patients’ access to appropriate care.

Samantha Fox: As we’ve mentioned, the clinical challenge isn’t necessarily identifying depressive symptoms but rather recognizing when a depressive presentation warrants further evaluation. This is based on the overall pattern of symptoms, course of illness, and family history. Mixed features adds another layer of complexity because manic or hypomanic symptoms may be embedded in an otherwise depressive presentation rather than occurring as a distinct episode. 

DSM-5 Diagnostic Criteria and Recognition: Anxious Distress 

Samantha Fox: Now, let’s turn our attention to a second prevalent specifier—the anxious distress specifier. Roughly 75% of adults with MDD report concurrent anxiety symptoms.5 As a way for clinicians to characterize these co-morbid anxiety symptoms, the DSM-5 introduced the anxious distress specifier. Recognizing this specifier is clinically consequential as it can be associated with a more severe course of illness.

The anxious distress specifier applies to any mood episode in which at least 2 of 5 anxiety symptoms are present on most days. These symptoms can include feeling keyed up or tense, feeling unusually restless, difficulty concentrating because of worry, fear that something awful might happen, or a feeling of losing control. Severity is graded as mild with 2 symptoms present, moderate with 3 symptoms, moderate to severe with 4 to 5 symptoms, and severe when 4 to 5 symptoms occur alongside psychomotor agitation.

In a study of adults with MDD, anxious distress occurred in approximately 75% of cases and was associated with earlier onset, more lifetime depressive episodes, longer episode duration, and higher suicidality. Compared to patients who do not express this specifier, patients with anxious distress may struggle more at work and in their relationships. 

Jamie Fernandez: Ok. So, for the clinician in this scenario, the diagnostic task is not simply recognizing the primary diagnosis of major depressive disorder or bipolar disorder but also assessing the presence of potential co-morbid anxiety symptoms, as this is a common presentation. It is about understanding the full clinical picture so that a patient can be provided the most appropriate treatment plan.

This also underscores why recognizing the anxious distress specifier matters in the first place. It offers a way to characterize what’s happening during the mood episode itself, adding another data point to the longitudinal assessment and bringing the bigger picture into focus. 

Summary & Key Takeaways

Samantha Fox: To summarize our conversation today, specifiers are additional descriptors that highlight a specific symptom pattern alongside a confirmed DSM-5 diagnosis, and this can impact a patient’s management plan. Mixed features and anxious distress are the two specifiers we’ve discussed today. The anxious distress specifier can apply to three-quarters of patients diagnosed with MDD, and the mixed features specifier has been reported to approximately 15% of adults with lifetime MDD. When looking at current-episode prevalence, the mixed features specifier is present in roughly one-quarter of patients with MDD and one-third of patients with bipolar disorder.

Let’s cover the key takeaways for this episode. Dr Fernandez, can you walk us through the clinical pearls from our discussion? 

Jamie Fernandez: Absolutely! I'd be happy to. Mixed features and anxious distress are DSM-5 specifiers that can be applied to patients with an MDD or bipolar disorder diagnosis. They may be associated with earlier disease onset, a more severe illness course, and greater functional impairment, even after controlling for symptom severity.

The anxious distress specifier is characterized by the presence of at least two specified anxiety symptoms. The mixed features specifier requires that there to be at least three manic or hypomanic symptoms present—such as elevated mood, increased energy, or decreased need for sleep—during a major depressive episode. The mixed features specifier applies in the reverse direction as well: a manic or hypomanic episode accompanied by three or more depressive symptoms also qualifies.

Mood symptoms are often first encountered in primary care, and mixed features and anxious distress are common symptom patterns that present in some patients with MDD or bipolar disorder. Provider awareness of these presentations can support more informed evaluation and management, ultimately improving a patient’s experience throughout their individual treatment journey.

I want to thank the audience for listening to our discussion today, and for more educational content on mood disorders, please visit PrimaryCarePsychiatry.com.

Disclaimer

This content has been created for US health care professionals and is intended for information and educational purposes only. It should not be used to replace clinical judgment or a discussion with the patient’s health care team. All decisions regarding patient diagnosis and care must be made by a qualified health care professional based on each patient’s individual needs.

Referenced tools are adjunctive aids and are not diagnostic on their own, and this resource does not endorse or recommend any specific drug, treatment, or manufacturer.